Takaisin

Effect of semaglutide on weight loss and cardiovascular events in obese or overweight adults

Näytönastekatsaukset
Yasmina Silén and Bianca Arrhenius
17.11.2026

Level of evidence: A

In adults with BMI≥30 kg/m2 or BMI≥27 kg/m2 and at least one weight-related comorbidity, once-weekly subcutaneous semaglutide 2.4 mg results in substantial weight loss compared to placebo, with a mean difference of approximately 11-12%, over follow-up periods ranging from 1-3 years. Individuals with type II diabetes typically present somewhat lower weight loss percentages; mean difference compared to placebo: 6-7%.

Semaglutide also probably reduces the incidence of major cardiovascular events in adults with established cardiovascular disease.

Comment: Cochrane review on the topic «Bracchiglione J, Meza N, Franco JV, et al. Semaglu...»7 was published in 2025. We chose not to include it in this evidence summary, because the review includes trials where obesity or overweight was not the target of the intervention, and therefore dosage and administration routes in some of the trials differed from those that aim to treat obesity.

Table 1. Description of the included studies
Reference Study type and design Population Intervention and comparison Outcomes Risk of bias
RCT=randomized controlled trial; SR=systematic review; MA=meta-analysis
«Moiz A, Levett JY, Filion KB, et al. Long-Term Eff...»1 Moiz 2024 includes STEP 1, 3, 5 and 8 Systematic review and meta-analysis of 4 RCTs. Efficiency for weight loss among individuals without diabetes 3,087 adults ≥18 years of age with BMI≥30 kg/m2 or BMI≥27 kg/m2 and at least one weight-related comorbidity,
without diabetes, recruited from multiple countries.
Intervention: Once-weekly subcutaneous semaglutide 2.4 mg + lifestyle intervention (diet and physical activity). Comparison: Placebo injection + identical lifestyle intervention. Primary: % change in body weight. Secondary: ≥5%, ≥10%, ≥15%, ≥20% weight loss; change in absolute body weight, BMI, adverse events Low
«Davies M, Færch L, Jeppesen OK, et al. Semaglutide...»2 Davies 2021
STEP 2-study
Multicenter RCT: weight loss efficiency among patients with type II diabetes 1,210 adults with a BMI of at least 27 kg/m2 and HbA1c 7–10% (53–86 mmol/mol) and diagnosis of type II diabetes
149 outpatient clinics in 12 countries.
1) semaglutide 2.4 mg
2) semaglutide 1.0 mg
3) visually matching placebo
All groups received a lifestyle intervention. Use of peroral drugs for diabetes was permitted.
Percentage change in bodyweight and achievement of weight reduction of at least 5%.
Safety
Low
«Ryan DH, Lingvay I, Deanfield J, et al. Long-term ...»3 Ryan 2024 SELECT trial post hoc analysis RCT (prespecified post hoc analysis, 4-year follow-up) 17,604 adults aged ≥45 years with established cardiovascular disease, overweight or obesity (BMI ≥27 kg/m²), and no diabetes, 804 sites across 41 countries. Intervention: Once-weekly subcutaneous semaglutide 2.4 mg Comparison: Matching placebo. Primary outcome for this analysis: Change in body weight (%), at 208 weeks.
Safety.
Low
«McGowan BM, Bruun JM, Capehorn M, et al. Efficacy ...»4 McGowan 2024
STEP 10-study
Multicenter RCT: efficacy for weight loss and reversion of prediabetes, off-treatment follow-up results. 207 participants aged 18 years or older with a BMI of ≥30 kg/m² and prediabetes (HbA1c 6–6.4%, 42-47 mmol/mol or fasting plasma glucose 5.5-6.9 mmol/L)
30 trial sites in Canada, Denmark, Finland, Spain, and the UK.
Semaglutide 2.4 mg subcutaneously once weekly compared to placebo, both with lifestyle intervention.
Dose escalation to 2.4 mg over 16 weeks, treatment lasted 52 weeks followed by 28-week off-treatment period.
Primary endpoints: Bodyweight change (%) and reversion to normoglycemia at week 52.
Secondary endpoints: Changes in weight (kg), glycemic, and cardiometabolic outcomes and proportions achieving ≥5–20% weight loss at week 52.
Exploratory endpoints: Bodyweight, glycemic, and cardiometabolic outcomes up to week 80.
Low
«Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. S...»5 Lincoff 2023
SELECT-study
Multicenter RCT: cardiovascluar events among patients using semaglutide vs placebo 17,604 adults aged ≥45 years with preexisting cardiovascular disease and overweight or obesity without diabetes mellitus, recruited from 41 countries Semaglutide 2.4 mg subcutaneously once weekly compared to placebo Composite cardiovascular outcome (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke), body weight change, safety and adverse events Low
«Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Se...»6 Kosiborod 2023 Multicenter RCT: heart failure symptoms and events 529 patients (mean age 69 years; 56% women) with heart failure with preserved ejection fraction (HFpEF, LVEF ≥45%, NYHA class II-IV) and obesity (BMI ≥30 kg/m²), without diabetes. Conducted at 96 sites in 13 countries. Intervention: Once-weekly subcutaneous semaglutide 2.4 mg for 52 weeks
Comparison: Placebo
Outcome: heart failure events
Other outcomes, not reported here: Change in KCCQ-CSS and body weight at 52 weeks. Secondary outcomes: 6-minute walk distance, CRP level
Table 2. Additional comments for included studies
Reference Comments
«Moiz A, Levett JY, Filion KB, et al. Long-Term Eff...»1 Moiz 2024 Risk of bias was rated with the Cohrane risk of bias-tool. 3/4 RCTs were considered to have low risk of bias, one RCT (STEP 8) had some concerns related to deviations from the intended intervention and suspected selective reporting.
«Davies M, Færch L, Jeppesen OK, et al. Semaglutide...»2 Davies 2021 ~25% per group discontinued the study. The proportion was nearly the same across groups and reasons were reported.
Significant improvements were seen in the intervention groups for HbA1c, fasting glucose, systolic blood pressure and physical functioning compared to placebo. LDL measurements did not differ between groups post-treatment. Industry-funded.
«Ryan DH, Lingvay I, Deanfield J, et al. Long-term ...»3 Ryan 2024 Same dataset as Lincoff et al. Post-hoc analysis.
Clinically meaningful weight loss occurred in both sexes
and all races, body sizes and regions. Semaglutide was associated with fewerserious adverse events. For each BMI category (<30, 30 to <35, 35 to <40 and
≥40 kg m−2) there were lower rates (events per 100 years of observation) of
serious adverse events with semaglutide. Weight loss plateau was reached at approximately 1 year and then results were maintained in the semaglutide group. Surprisingly, the placebo group also lost weight, even though no lifestyle intervention was provided to either group.
«McGowan BM, Bruun JM, Capehorn M, et al. Efficacy ...»4 McGowan 2024 71% of the study subjects were female. High treatment adherence: 87% completed treatment (120 in the semaglutide 2.4 mg group
and 61 (88%) in the placebo group), 93% completed the trial (128 in the semaglutide 2.4 mg group and 64 in the placebo group).
The reported changes in bodyweight from baseline to week 80 (weeks 52-80 off treatment) indicate partial bodyweight regain from week 52 to week 80; although bodyweight had not returned to baseline levels, the bodyweight trajectory continued upward at the end of the observation period. Industry-funded.
«Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. S...»5 Lincoff 2023 Large, randomized controlled trial with adequate randomization, double-blinding, and prespecified outcomes. High follow-up rate (96.9%). Discontinuation due to adverse events was slightly higher in the semaglutide group. Industry-funded.
Only the cardiovascular endpoints from this study are reported here.
«Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Se...»6 Kosiborod 2023 Only the heart failure endpoints from this study are reported here. Low number of heart-failure events (1 vs 12), introducing possible imprecision. 97% completed the 52-week follow-up; balanced discontinuation rates between groups (16% vs 16%). Industry-funded.

Results

Table 3. Weight loss
Reference Number of studies and number of patients (I/C) Follow-up time Weight loss in kg:s mean, (%) I Weight loss in kg:s mean, (%) C Estimated treatment difference (95% CI)
Level of evidence: high
I= intervention; C=comparison; CI=confidence interval
«Moiz A, Levett JY, Filion KB, et al. Long-Term Eff...»1 Moiz 2024 4 RCTs
Semaglutide 2.4 mg
n= 1991
Placebo
n=1096
68–111 weeks –15.7 kg (-15.1 %) –3.3 kg (–3.0%) –12.3 kg (95% CI –13.6 to –11.0; –12.1% (95% CI –13.5 to –10.7%)
«Davies M, Færch L, Jeppesen OK, et al. Semaglutide...»2 Davies 2021 Semaglutide 2.4 mg
n=404
Semaglutide 1.0 mg
n=403
Placebo
n=403
68 weeks Semaglutide 2.4 mg:
−9.7 kg (-9.6 %)
Semaglutide 1.0 mg
−6.9 kg (-7.0 %)
Placebo
−3.5 kg (-3.4 %)
Semaglutide 2.4 mg vs placebo: −6.1 kg (−7.2 to −5.0)
−6.2% (−7.3 to −5.5%)
«Ryan DH, Lingvay I, Deanfield J, et al. Long-term ...»3 Ryan 2024 Semaglutide 2.4 mg
n= 8803
Placebo
n=8801
208 weeks −10.2% −1.5% −8.7% (−9.4 to −7.9%)
«McGowan BM, Bruun JM, Capehorn M, et al. Efficacy ...»4 McGowan 2024 Semaglutide 2.4 mg
n=138
Placebo
n=69
52 weeks −15.2 kg (−13.9%) −2.8 kg (−2.7%) −11.2% (−13.0 to −9.4%)
80 weeks (last 28 weeks off treatment for both groups) −8.7 kg
(-7.9%)
-1.2 kg (-1.3%) -6.6%
Table 4. Weight loss 5%, 10%, 15%, 20%
Reference Number of studies and number of patients (I/C) Follow-up time Absolute number of events (%) I Absolute number of events (%) C Odds ratio or relative risk (95% CI) Semaglutide vs placebo
Level of evidence: high
I= intervention; C=comparison; CI=confidence interval
«Moiz A, Levett JY, Filion KB, et al. Long-Term Eff...»1 Moiz 2024 4 RCTs
Semaglutide 2.4mg
n= 1991
Placebo
n=1096
68–111 weeks ≥5% weight loss: 1694/1974 (85.8%) ≥5%: 370/1065 (34.7%) RR 2.37 (1.67–3.36)
≥10% weight loss: 1381/1974 (70.0%) ≥10%: 163/1065 (15.3%) RR 4.27 (2.55–7.15)
≥15% weight loss: 1027/1974 (52.0%) ≥15%: 73/1065 (6.8%) RR 7.12 (3.66–13.85)
≥20% weight loss: 660/1974 (33.4%) ≥20%: 23/1065 (2.2%) RR 15.08 (9.31–24.43)
«Davies M, Færch L, Jeppesen OK, et al. Semaglutide...»2 Davies 2021 Semaglutide 2.4 mg
n=404
Placebo n=403
68 weeks ≥5% weight loss:
267/388 (68.8%)
≥5%:
107/376 (28.5%)
5%:
OR 4.9 (3.6-6.6)
≥10% weight loss: 177/388 (45.6%) ≥10%:
31/376 (8.2%)
10%:
OR 7.4 (4.9–11.2)
≥15% weight loss: 100/388 (25.8%) ≥15%:
12/376 (3.2%)
15%:
OR 7.7 (4.1–14.2)
«Ryan DH, Lingvay I, Deanfield J, et al. Long-term ...»3 McGowan 2024 Semaglutide 2.4 mg
n=138
Placebo
n=69
52 weeks ≥5% weight loss: 11/129 (86%) ≥5%: 17/66 (26%) ≥5%: OR 15.9 (7.5–33.6)
≥10% weight loss: 95/129 (74%) ≥10%: 5/66 (8%) ≥10%: OR 32.7 (12.0–89.1)
≥15% weight loss: 62/129 (48%) ≥15%: 1/66 (2%) ≥15%: OR 52.2 (7.1–383.1)
Table 5. Cardiovascular and heart failure end points
Reference Number of studies and number of patients (I/C) Follow-up time Absolute number of events (%) I Absolute number of events (%) C Hazard ratio (95% CI)
Level of evidence: moderate
The quality of evidence is downgraded due to study limitations (short follow-up time for cardiovascular events) and imprecision.
I= intervention; C=comparison; CI=confidence interval
«Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. S...»5 Lincoff 2023 Semaglutide 2.4 mg
n=8803
Placebo
n=8801
39.8 months Cardiovascular death, nonfatal myocardial infarction, nonfatal stroke:
569 (6.5%)
Cardiovascular death, nonfatal myocardial infarction, nonfatal stroke:
701 (8.0%)
0.80 (0.72–0.90)
Cardiovascular death:
223 (2.5%)
Cardiovascular death:
262 (3.0%)
0.85 (0.71–1.01)
Nonfatal myocardial infarction: 234 (2.7%) Nonfatal myocardial infarction: 322 (3.7%) 0.72 (0.61–0.85)
Hospitalization or urgent medical visit for heart failure: 97 (1.1%) Hospitalization or urgent medical visit for heart failure: 122 (1.4%) 0.79 (0.60–1.03)
«Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Se...»6 Kosiborod Semaglutide
n=263
Placebo
n=266
52 weeks Heart failure events 1/263 (0.4%) Heart failure events 12/266 (4.5%) 0.08 (95% CI 0.00–0.42)

References

  1. Moiz A, Levett JY, Filion KB, et al. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Cardiol 2024;222():121-130 «PMID: 38679221»PubMed
  2. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021;397(10278):971-984 «PMID: 33667417»PubMed
  3. Ryan DH, Lingvay I, Deanfield J, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med 2024;30(7):2049-2057 «PMID: 38740993»PubMed
  4. McGowan BM, Bruun JM, Capehorn M, et al. Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol 2024;12(9):631-642 «PMID: 39089293»PubMed
  5. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389(24):2221-2232 «PMID: 37952131»PubMed
  6. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med 2023;389(12):1069-1084 «PMID: 37622681»PubMed
  7. Bracchiglione J, Meza N, Franco JV, et al. Semaglutide for adults living with obesity. Cochrane Database Syst Rev 2025;10(10):CD015092 «PMID: 41161683»PubMed